JPH10506385A - がんを治療するための化合物及び方法 - Google Patents
がんを治療するための化合物及び方法Info
- Publication number
- JPH10506385A JPH10506385A JP8509705A JP50970596A JPH10506385A JP H10506385 A JPH10506385 A JP H10506385A JP 8509705 A JP8509705 A JP 8509705A JP 50970596 A JP50970596 A JP 50970596A JP H10506385 A JPH10506385 A JP H10506385A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- cancerous
- cytosine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式 (式中、R1及びR2は水素、アシル及びC1〜C18のアルキルから成るグループ から選択される) の化合物のβ−L−鏡像異性体であって、対応するβ−D−鏡像異性体が少なく とも95%含まれていないβ−L−鏡像異性体。 2.R1及びR2が水素である請求項1に記載の化合物。 3.アルキル基がメチル、エチル、プロピル、ブチル、ペンチル、ヘキシル、 イソプロピル、イソブチル、sec-ブチル、t-ブチル、及びイソペンチルから成る グループから選択される請求項1に記載の化合物。 4.アシル基が−C(O)Rであり、RがC1〜C5のアルキル基、フェニル、 又はベンジルである請求項1に記載の化合物。 5.薬理学的に許容できる担体中に、宿主動物の腫瘍を治療するのに有効な量 の請求項1又は請求項2に記載の化合物、又はその薬理学的に許容できる塩を含 む医薬組成物。 6.担体が経口送達に適している請求項5に記載の組成物。 7.担体が静脈内送達に適している請求項5に記載の組成物。 8.担体が局所送達又は経皮送達に適している請求項5に記載の組成物。 9.請求項1又は請求項2に記載の化合物の有効量を宿主動物に投与すること を含む宿主動物の腫瘍を治療する方法。 10.宿主動物がヒトである請求項9に記載の方法。 11.腫瘍ががん性であり、がんが前立腺がんである請求項9に記載の方法。 12.腫瘍ががん性であり、がんが白血病である請求項9に記載の方法。 13.腫瘍ががん性であり、がんが結腸がんである請求項9に記載の方法。 14.腫瘍ががん性であり、がんが膀胱がんである請求項9に記載の方法。 15.腫瘍ががん性であり、がんが肝細胞がんである請求項9に記載の方法。 16.腫瘍ががん性であり、がんが乳がんである請求項9に記載の方法。 17.腫瘍ががん性であり、がんが肺がんである請求項9に記載の方法。 18.腫瘍ががん性であり、がんが鼻咽頭がんである請求項9に記載の方法。 19.腫瘍ががん性であり、がんが膵臓がんである請求項9に記載の方法。 20.腫瘍ががん性であり、がんが卵巣がんである請求項9に記載の方法。 21.腫瘍ががん性であり、がんがリンパ腫である請求項9に記載の方法。 22.腫瘍ががん性であり、がんが肝細胞がんである請求項9に記載の方法。 23.薬理学的に許容できる担体中に適宜含ませた、式 (式中、RはH、F、−CH3、−C(H)=CH2、−C=CH、又は−C≡N 、−Br、−NO2から成るグループから選択され、R1及びR2は水素、アルキ ル、アシル、モノフォスフェート、ジフォスフェート、及びトリフォスフェート から 成るグループから選択される) の化合物、又はその薬理学的に許容できる塩の有効量を投与することを含む、宿 主のがんを治療する方法。 24.Rがフッ素であり、R1及びR2が水素である請求項23に記載の方法。 25.宿主動物がヒトである請求項23又は請求項24に記載の方法。 26.腫瘍ががん性であり、がんが前立腺がんである請求項23又は請求項2 4に記載の方法。 27.腫瘍ががん性であり、がんが白血病である請求項23又は請求項24に 記載の方法。 28.腫瘍ががん性であり、がんが結腸がんである請求項23又は請求項24 に記載の方法。 29.腫瘍ががん性であり、がんが膀胱がんである請求項23又は請求項24 に記載の方法。 30.腫瘍ががん性であり、がんが肝細胞がんである請求項23又は請求項2 4に記載の方法。 31.腫瘍ががん性であり、がんが乳がんである請求項23又は請求項24に 記載の方法。 32.腫瘍ががん性であり、がんが肺がんである請求項23又は請求項24に 記載の方法。 33.腫瘍ががん性であり、がんが鼻咽頭がんである請求項23又は請求項2 4に記載の方法。 34.腫瘍ががん性であり、がんが膵臓がんである請求項23又は請求項24 に記載の方法。 35.腫瘍ががん性であり、がんが卵巣がんである請求項23又は請求項24 に記載の方法。 36.腫瘍ががん性であり、がんがリンパ腫である請求項23又は請求項24 に記載の方法。 37.腫瘍ががん性であり、がんが肝細胞がんである請求項23又は請求項2 4に記載の方法。 38.薬理学的に許容できる担体中に、宿主動物の腫瘍を治療するのに有効な 量の請求項23又は請求項24に記載の化合物、又はその薬理学的に許容できる 塩を含む医薬組成物。 39.担体が経口送達に適している請求項23又は請求項24に記載の方法。 40.担体がカプセルを含む請求項9、請求項23又は請求項24に記載の方 法。 41.担体が錠剤の形である請求項9、請求項23又は請求項24に記載の方 法。 42.投与が非経口である請求項9、請求項23又は請求項24に記載の方法 。 43.式 (式中、R1aは水素、又はアシル基を含むヒドロキシ保護基であり、Lは離脱基 である。任意のヒドロキシ保護基を適宜はずしてもよい) の1,3-ジオキソランと、適宜保護されたシトシンとを反応させる工程を含む、( -)-(2S,4S)-1-(2-ヒドロキシメチル-1,3-ジオキソラン-4-yl)シトシンを調製 する方法。 44.式 (式中、R1aがヒドロキシ保護基である) の化合物を、ウラシル環の4位のオキソ基をアミノ基に変換する薬剤と反応させ る工程と、次に保護基をはずす工程とを含む、2-ヒドロキシメチル-5-(シトシン -1-yl)-1,3-ジオキソランを調製する方法。 45.生成物をラセミ化させないルイス酸を使用して、式 の保護された1,3-ジオキソランを、5位で適宜置換されている保護されたシト シン塩基と反応させる工程を含む、(2S,4S)-1-(2-ヒドロキシメチル-1,3-ジオ キソラン-4-yl)シトシンを調製する方法。 46.医学療法、たとえばがん性腫瘍を含む腫瘍の治療及び予防に使用するた めの、(-)-(2S,4S)-1-(2-ヒドロキシメチル-1,3-ジオキソラン-4-yl)シトシン 及びその誘導体類及び塩類、又はその(+)鏡像異性体又はラセミ混合物、及び その薬理学的に許容できる誘導体類及び塩類。 47.がん性腫瘍を含む腫瘍治療用の薬剤の製造における、(-)-(2S,4S)-1-( 2-ヒドロキシメチル-1,3-ジオキソラン-4-yl)シトシン及びその薬理学的に許容 できる誘導体類及び塩類、又はその(+)鏡像異性体又はラセミ混合物、及び その薬理学的に許容できる誘導体類及び塩類の使用。 48.医学療法、たとえば細胞の異常増殖又は望ましくない増殖の治療及び予 防に使用するための、(-)-(2S,4S)-1-(2-ヒドロキシメチル-1,3-ジオキソラン -4-yl)シトシン及びその誘導体類及び塩類、又はその(+)鏡像異性体又はラセ ミ混合物、及びその薬理学的に許容できる誘導体類及び塩類。 49.細胞の異常増殖又は望ましくない増殖を治療するための薬剤の製造にお ける、(-)-(2S,4S)-1-(2-ヒドロキシメチル-1,3-ジオキソラン-4-yl)シトシン 及びその薬理学的に許容できる誘導体類及び塩類、又はその(+)鏡像異性体又 はラセミ混合物、及びその薬理学的に許容できる誘導体類及び塩類の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/301,298 | 1994-09-06 | ||
US08/301,298 US5817667A (en) | 1991-04-17 | 1994-09-06 | Compounds and methods for the treatment of cancer |
US39063395A | 1995-02-17 | 1995-02-17 | |
US08/390,633 | 1995-02-17 | ||
PCT/US1995/011464 WO1996007413A1 (en) | 1994-09-06 | 1995-09-05 | Compounds and methods for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10506385A true JPH10506385A (ja) | 1998-06-23 |
JP3979662B2 JP3979662B2 (ja) | 2007-09-19 |
Family
ID=26972285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50970596A Expired - Lifetime JP3979662B2 (ja) | 1994-09-06 | 1995-09-05 | がんを治療するための化合物及び方法 |
Country Status (31)
Country | Link |
---|---|
US (3) | US6063787A (ja) |
EP (2) | EP0781136B1 (ja) |
JP (1) | JP3979662B2 (ja) |
KR (1) | KR100374477B1 (ja) |
CN (3) | CN1827108A (ja) |
AP (1) | AP783A (ja) |
AT (1) | ATE267015T1 (ja) |
AU (1) | AU704977B2 (ja) |
BG (1) | BG63122B1 (ja) |
BR (1) | BR9508886A (ja) |
CA (1) | CA2199117C (ja) |
CZ (1) | CZ297873B6 (ja) |
DE (1) | DE69533066T2 (ja) |
DK (1) | DK0781136T3 (ja) |
ES (1) | ES2219666T3 (ja) |
FI (1) | FI970918A (ja) |
HU (1) | HUT77172A (ja) |
IL (1) | IL115156A (ja) |
IS (1) | IS2011B (ja) |
MY (1) | MY121548A (ja) |
NO (1) | NO313268B1 (ja) |
NZ (1) | NZ335013A (ja) |
OA (1) | OA10473A (ja) |
PL (2) | PL188359B1 (ja) |
PT (1) | PT781136E (ja) |
RO (1) | RO118748B1 (ja) |
RU (1) | RU2168995C2 (ja) |
SI (1) | SI0781136T1 (ja) |
SK (1) | SK284564B6 (ja) |
WO (1) | WO1996007413A1 (ja) |
ZA (1) | ZA957483B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540142A (ja) * | 1999-03-29 | 2002-11-26 | シャイアー・バイオケム・インコーポレイテッド | 白血病の処置方法 |
JP2009518393A (ja) * | 2005-12-08 | 2009-05-07 | クラヴィス・ファルマ・アーエス | がん治療用ジオキソラン誘導体 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US6069252A (en) * | 1990-02-01 | 2000-05-30 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
CN1307421C (zh) | 1997-08-08 | 2007-03-28 | 塞米得肿瘤学美国公司 | 克服生物及化学治疗抗性的方法与组合物 |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
DE69900841T2 (de) | 1998-01-23 | 2002-10-02 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
BR9908270A (pt) | 1998-02-25 | 2004-06-29 | Univ Emory | 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos |
AU2004201676B2 (en) * | 1999-03-29 | 2006-03-09 | University Of Georgia Research Foundation, Inc. | Methods of treating leukemia |
US6653318B1 (en) | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US6583149B1 (en) | 1999-09-24 | 2003-06-24 | Biochem Pharma Inc. | Method for the treatment or prevention of viral infection using nucleoside analogues |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
EP1600452A3 (en) | 1999-11-12 | 2008-09-10 | Pharmasset, Inc. | Synthesis of 2'-deoxy-L-nucleosides |
PL361310A1 (en) * | 2000-10-13 | 2004-10-04 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
CA2441350A1 (en) | 2001-01-19 | 2002-07-25 | Newbiotics, Inc. | Methods to treat autoimmune and inflammatory conditions |
CN1744902B (zh) * | 2001-03-23 | 2010-05-26 | 希拉加拿大股份有限公司 | 治疗癌症的药物组合 |
DE60234577D1 (de) | 2001-03-23 | 2010-01-14 | Shire Canada Inc | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält |
US20030027799A1 (en) * | 2001-03-30 | 2003-02-06 | Shire Biochem Inc. | Methods of treating cancer using a combination of drugs |
AU2002336864B2 (en) * | 2001-11-02 | 2006-08-17 | Shire Biochem Inc. | Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs |
PT1448186E (pt) * | 2001-11-19 | 2009-03-24 | Medigene Ag | Medicamento para o tratamento de doenças virais da pele e doenças tumorais |
JP4299779B2 (ja) | 2002-06-21 | 2009-07-22 | エルジー エレクトロニクス インコーポレーテッド | ビデオデータの再生を管理するためのデータ構造を有する記録媒体 |
MXPA04002365A (es) | 2002-06-21 | 2004-11-22 | Lg Electronics Inc | Medio de grabacion que tiene estructura de datos para manejar la reproduccion de datos de video grabados en el mismo. |
KR20040000290A (ko) | 2002-06-24 | 2004-01-03 | 엘지전자 주식회사 | 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법 |
WO2004001751A1 (en) | 2002-06-24 | 2003-12-31 | Lg Electronics Inc. | Recording medium having data structure including navigation control information for managing reproduction of video data recorded thereon and recording and reproducing methods and apparatuses |
CA2459086C (en) | 2002-06-28 | 2013-08-13 | Lg Electronics Inc. | Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus |
RU2347284C2 (ru) | 2002-10-14 | 2009-02-20 | Эл Джи Электроникс Инк. | Носитель записи со структурой данных для управления воспроизведением записанного на нем множества аудиопотоков и способы и устройства записи и воспроизведения |
CN100479051C (zh) | 2002-10-15 | 2009-04-15 | Lg电子有限公司 | 具有管理多路图形流重现的数据结构的记录介质及记录和重现方法和装置 |
US7720356B2 (en) | 2002-11-12 | 2010-05-18 | Lg Electronics Inc | Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses |
US7664372B2 (en) | 2002-11-20 | 2010-02-16 | Lg Electronics Inc. | Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses |
US7693394B2 (en) | 2003-02-26 | 2010-04-06 | Lg Electronics Inc. | Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses |
US7809775B2 (en) | 2003-02-27 | 2010-10-05 | Lg Electronics, Inc. | Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses |
EP1604356A4 (en) | 2003-02-28 | 2009-12-16 | Lg Electronics Inc | RECORD MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE RANDOM / SHUFFLE PLAYBACK OF RECORDED VIDEO DATA, AND METHOD AND DEVICES FOR RECORDING AND PLAYING |
US7620301B2 (en) | 2003-04-04 | 2009-11-17 | Lg Electronics Inc. | System and method for resuming playback |
AU2004281525B2 (en) | 2003-10-09 | 2010-01-28 | Aresus Pharma GmbH | The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
CN103735560A (zh) | 2005-06-07 | 2014-04-23 | 耶鲁大学 | 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法 |
US7951788B2 (en) * | 2005-12-02 | 2011-05-31 | Yale University | Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs |
CN101534835B (zh) * | 2006-09-01 | 2012-05-30 | 佐治亚大学研究基金会 | 用于癌症的L-OddC的前药 |
CN102406649A (zh) * | 2011-11-15 | 2012-04-11 | 张始状 | 人体五种正常碱基在制备治疗肿瘤药物中的应用 |
CN103720693A (zh) * | 2011-11-15 | 2014-04-16 | 张始状 | 人体五种正常碱基在制备治疗肿瘤药物中的应用 |
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
CN110168092A (zh) * | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
SG10201708886RA (en) * | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
EP0206497B1 (en) * | 1985-05-15 | 1994-07-20 | The Wellcome Foundation Limited | Therapeutic nucleosides and their preparation |
JPS62501712A (ja) * | 1985-08-26 | 1987-07-09 | アメリカ合衆国 | 2′、3′―ジデオキシイノシン、2′,3′―ジデオキシグアノシンまたは2′,3′―ジデオキシアデノシンを含有する抗htlv―3/lav剤 |
US4879277A (en) * | 1985-08-26 | 1989-11-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral compositions and methods |
DK167377B1 (da) * | 1985-09-17 | 1993-10-25 | Wellcome Found | 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion |
IN164556B (ja) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
FR2601385B1 (fr) * | 1986-07-09 | 1989-09-29 | Sucre Rech & Dev | Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus |
US4963533A (en) * | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
NZ223990A (en) * | 1987-03-24 | 1990-08-28 | Nycomed As | Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions |
US5185437A (en) * | 1987-04-09 | 1993-02-09 | Burroughs Wellcome Co. | Therapeutic nucleosides |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US4900828A (en) * | 1988-05-12 | 1990-02-13 | Hoffmann-Laroche Inc. | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine |
SE8802687D0 (sv) * | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
EP0375329B1 (en) * | 1988-12-19 | 1995-05-31 | The Wellcome Foundation Limited | Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them |
UA45942A (uk) * | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5071983A (en) * | 1989-10-06 | 1991-12-10 | Burroughs Wellcome Co. | Therapeutic nucleosides |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
IE904378A1 (en) * | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5700937A (en) * | 1990-02-01 | 1997-12-23 | Emory University | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5527782A (en) * | 1990-03-13 | 1996-06-18 | Acic (Canada) Inc. | 5-halo-2,3'-O-cyclocytidines |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
AU9125991A (en) * | 1990-12-05 | 1992-07-08 | University Of Georgia Research Foundation, Inc., The | Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
NZ250842A (en) * | 1991-02-22 | 1996-03-26 | Univ Emory | Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc) |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
SK279542B6 (sk) * | 1991-03-06 | 1998-12-02 | The Wellcome Foundation Limited | U |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923640B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9111902D0 (en) * | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
GB9226927D0 (en) | 1992-12-24 | 1993-02-17 | Iaf Biochem Int | Dideoxy nucleoside analogues |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
WO1995018137A1 (en) * | 1993-12-30 | 1995-07-06 | Genta Incorporated | Improved process for the purification of oligomers |
US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5971983A (en) * | 1997-05-09 | 1999-10-26 | The Regents Of The University Of California | Tissue ablation device and method of use |
-
1995
- 1995-09-04 IL IL11515695A patent/IL115156A/xx not_active IP Right Cessation
- 1995-09-05 AT AT95933071T patent/ATE267015T1/de not_active IP Right Cessation
- 1995-09-05 BR BR9508886A patent/BR9508886A/pt not_active Application Discontinuation
- 1995-09-05 JP JP50970596A patent/JP3979662B2/ja not_active Expired - Lifetime
- 1995-09-05 RU RU97105381/04A patent/RU2168995C2/ru not_active IP Right Cessation
- 1995-09-05 CZ CZ0063397A patent/CZ297873B6/cs not_active IP Right Cessation
- 1995-09-05 CN CNA2006100549917A patent/CN1827108A/zh active Pending
- 1995-09-05 EP EP95933071A patent/EP0781136B1/en not_active Expired - Lifetime
- 1995-09-05 WO PCT/US1995/011464 patent/WO1996007413A1/en active IP Right Grant
- 1995-09-05 US US08/809,007 patent/US6063787A/en not_active Expired - Fee Related
- 1995-09-05 DE DE69533066T patent/DE69533066T2/de not_active Expired - Lifetime
- 1995-09-05 PL PL95318971A patent/PL188359B1/pl not_active IP Right Cessation
- 1995-09-05 SK SK281-97A patent/SK284564B6/sk not_active IP Right Cessation
- 1995-09-05 CA CA002199117A patent/CA2199117C/en not_active Expired - Fee Related
- 1995-09-05 DK DK95933071T patent/DK0781136T3/da active
- 1995-09-05 HU HU9701687A patent/HUT77172A/hu unknown
- 1995-09-05 AU AU35862/95A patent/AU704977B2/en not_active Ceased
- 1995-09-05 KR KR1019970701464A patent/KR100374477B1/ko not_active IP Right Cessation
- 1995-09-05 PT PT95933071T patent/PT781136E/pt unknown
- 1995-09-05 RO RO97-00419A patent/RO118748B1/ro unknown
- 1995-09-05 AP APAP/P/1997/000939A patent/AP783A/en active
- 1995-09-05 ES ES95933071T patent/ES2219666T3/es not_active Expired - Lifetime
- 1995-09-05 SI SI9530703T patent/SI0781136T1/xx unknown
- 1995-09-05 EP EP04003357A patent/EP1468687A1/en not_active Withdrawn
- 1995-09-05 PL PL95358979A patent/PL189288B1/pl not_active IP Right Cessation
- 1995-09-05 CN CN95195621A patent/CN1111409C/zh not_active Expired - Lifetime
- 1995-09-06 ZA ZA957483A patent/ZA957483B/xx unknown
- 1995-09-06 MY MYPI95002637A patent/MY121548A/en unknown
-
1997
- 1997-03-03 OA OA60972A patent/OA10473A/en unknown
- 1997-03-04 FI FI970918A patent/FI970918A/fi unknown
- 1997-03-04 IS IS4434A patent/IS2011B/is unknown
- 1997-03-05 BG BG101284A patent/BG63122B1/xx unknown
- 1997-03-05 NO NO19971015A patent/NO313268B1/no not_active IP Right Cessation
-
1999
- 1999-04-01 NZ NZ335013A patent/NZ335013A/xx not_active IP Right Cessation
-
2003
- 2003-04-18 CN CNB031106706A patent/CN1251680C/zh not_active Expired - Lifetime
- 2003-08-22 US US10/646,980 patent/US7262213B2/en not_active Expired - Lifetime
-
2007
- 2007-03-05 US US11/713,975 patent/US8076347B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540142A (ja) * | 1999-03-29 | 2002-11-26 | シャイアー・バイオケム・インコーポレイテッド | 白血病の処置方法 |
JP2009518393A (ja) * | 2005-12-08 | 2009-05-07 | クラヴィス・ファルマ・アーエス | がん治療用ジオキソラン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3979662B2 (ja) | がんを治療するための化合物及び方法 | |
US5817667A (en) | Compounds and methods for the treatment of cancer | |
BG63121B1 (bg) | Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат | |
US8399420B2 (en) | Azacytidine analogues and uses thereof | |
JPH10507772A (ja) | L−リボフラノシルヌクレオシド | |
HU211132A9 (en) | Nucleoside derivatives useful in treating retroviral infections | |
EP0180897B1 (en) | 5-fluorouracil derivatives | |
US6436948B1 (en) | Method for the treatment of psoriasis and genital warts | |
JP5185823B2 (ja) | がん治療用ジオキソラン誘導体 | |
KR20030017185A (ko) | N⁴-알킬옥시카르보닐-5-플루오로사이토신 유도체, 그의제조방법 및 이를 유효성분으로 포함하는 항암제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070417 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070612 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070626 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120706 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120706 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130706 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |